Novo Nordisk, a leader in breakthrough haemostasis research and treatment, inaugurated Novo Nordisk Research US, the first haemostasis research facility in the United States dedicated to life-threatening bleeding.
Researchers at the facility will investigate new therapies to prevent or stop critical bleeding, including exploration of treatments for intracerebral haemorrhage, trauma, stroke and other bleeding disorders, states the company release.
"Novo Nordisk is committed to discovering therapies to stop life-threatening bleeding, a major clinical problem. Our goal is to be a world leader in hemostasis care and the development partner of choice for academic and biotechnology researchers interested in breakthrough science," said Dr. Marcus Carr, head of Novo Nordisk Research US.
Scientists at Novo Nordisk Research US will be collaborating with academic institutions and industries in the area to further advance medical innovation.
Mads Krogsgaard Thomsen, chief science officer, Novo Nordisk global headquarters, Copenhagen, Denmark noted that the new centre, which represents a major expansion of Novo Nordisk's research in the area of haemostasis, is part of the ongoing internationalisation of the company's R&D.
With a unique Scandinavian design and a central research square surrounded by offices and laboratories, Novo Nordisk Research US is designed to create an open environment to encourage communication and collaboration among the scientists. The 30,000-square-foot facility, houses 21 full-time researchers, a staff size Novo Nordisk intends to double by the end of the year.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy, and hormone therapy for women.